David Krempa sold $504k of ETON
Chief Business Officer at Eton Pharmaceuticals, Inc.. 34,000 shares at an average of $14.83, traded Jun 12, 2025, filed Jun 16, 2025.
Score components
- +15RoleOfficer
- +18Trade size$504k at market
- 0Share of holdings soldSold 5.3% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-25-020518, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 12, 2025 | SOpen-market sale Common Stock | -16,977 | $14.92 | $253k | 629,669 | Jun 16, 2025 |
| Jun 13, 2025 | SOpen-market sale Common Stock | -6,800 | $14.77 | $100k | 622,869 | Jun 16, 2025 |
| Jun 16, 2025 | SOpen-market sale Common Stock | -10,223 | $14.73 | $151k | 612,646 | Jun 16, 2025 |
Related signals
Other insiders at Eton Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | ETONsell Eton Pharmaceuticals, Inc. | David Krempa Chief Business Officer | $229k 4,166 shares | -9% | |
| 47Moderate | ETONsell Eton Pharmaceuticals, Inc. | James R. Gruber Chief Financial Officer | $674k 41,713 shares | -17% | |
| 27Weak | ETONbuy Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $125k 7,930 shares | +0% | |
| 58Moderate | Eton Pharmaceuticals, Inc. | Sean Brynjelsen President & CEO | $3.6M 210,000 shares | -7% | |
| 11Weak | ETONbuy Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $80k 10,000 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.